Value of peripheral blood albumin and fibrinogen levels in the prognostic evaluation of advanced non-small cell lung cancer

Lin Quan, Ling-Tong Xu, Wenping Chen
{"title":"Value of peripheral blood albumin and fibrinogen levels in the prognostic evaluation of advanced non-small cell lung cancer","authors":"Lin Quan, Ling-Tong Xu, Wenping Chen","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.008","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical prognostic value of peripheral blood albumin and fibrinogen levels in advanced non-small cell lung cancer (NSCLC). \n \n \nMethods \nA total of 158 patients with advanced NSCLC who were admitted to Chest Hospital District of the Affiliated Brain Hospital of Nanjing Medical University from May 2010 to September 2015 were retrospectively analyzed. All patients received systemic chemotherapy plus or not local radiotherapy. The clinicopathological characteristics of patients and the results of peripheral serum protein and fibrinogen were collected, and the correlation between peripheral serum protein and fibrinogen levels and prognosis was analyzed. \n \n \nResults \nThe median level of serum albumin and plasma fibrinogen was 40.8 g/L (27.6-46.9 g/L) and 3.4 g (2.4-5.2 g/L), respectively, and the median serum albumin and fibrinogen ratio (AFR) was 12.1 (6.2-17.0). The median overall survival (OS) time in the increased serum albumin group (≥40 g/L) and the decreased serum albumin group (<40 g/L) was 17.0 and 9.0 months, respectively, and the median OS time in the increased plasma fibrinogen group (≥40 g/L) and the decreased plasma fibrinogen group (<40 g/L) was 9.0 and 17.0 months, respectively. The median OS time in the increased AFR group (≥10) and decreased AFR group (<10) was 17.0 and 8.0 months, respectively, and there were significant differences between two groups (all P < 0.01). Multivariate analysis showed that serum albumin level (HR = 1.58, 95% CI 1.20-2.06, P = 0.003), plasma fibrinogen level (HR = 1.43, 95% CI 1.01-2.03, P = 0.046) and AFR (HR = 1.81, 95% CI 1.22-2.62, P = 0.001) were independent prognostic factors of OS. \n \n \nConclusions \nIn patients with advanced NSCLC, higher albumin level and/or lower fibrinogen level are associated with better clinical prognosis. Peripheral serum albumin, fibrinogen level and AFR are independent prognostic factors for advanced NSCLC. \n \n \nKey words: \nCacinoma, non-small cell lung; Albumin; Fibrinogen; Prognosis","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"31 1","pages":"828-831"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To investigate the clinical prognostic value of peripheral blood albumin and fibrinogen levels in advanced non-small cell lung cancer (NSCLC). Methods A total of 158 patients with advanced NSCLC who were admitted to Chest Hospital District of the Affiliated Brain Hospital of Nanjing Medical University from May 2010 to September 2015 were retrospectively analyzed. All patients received systemic chemotherapy plus or not local radiotherapy. The clinicopathological characteristics of patients and the results of peripheral serum protein and fibrinogen were collected, and the correlation between peripheral serum protein and fibrinogen levels and prognosis was analyzed. Results The median level of serum albumin and plasma fibrinogen was 40.8 g/L (27.6-46.9 g/L) and 3.4 g (2.4-5.2 g/L), respectively, and the median serum albumin and fibrinogen ratio (AFR) was 12.1 (6.2-17.0). The median overall survival (OS) time in the increased serum albumin group (≥40 g/L) and the decreased serum albumin group (<40 g/L) was 17.0 and 9.0 months, respectively, and the median OS time in the increased plasma fibrinogen group (≥40 g/L) and the decreased plasma fibrinogen group (<40 g/L) was 9.0 and 17.0 months, respectively. The median OS time in the increased AFR group (≥10) and decreased AFR group (<10) was 17.0 and 8.0 months, respectively, and there were significant differences between two groups (all P < 0.01). Multivariate analysis showed that serum albumin level (HR = 1.58, 95% CI 1.20-2.06, P = 0.003), plasma fibrinogen level (HR = 1.43, 95% CI 1.01-2.03, P = 0.046) and AFR (HR = 1.81, 95% CI 1.22-2.62, P = 0.001) were independent prognostic factors of OS. Conclusions In patients with advanced NSCLC, higher albumin level and/or lower fibrinogen level are associated with better clinical prognosis. Peripheral serum albumin, fibrinogen level and AFR are independent prognostic factors for advanced NSCLC. Key words: Cacinoma, non-small cell lung; Albumin; Fibrinogen; Prognosis
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
外周血白蛋白和纤维蛋白原水平在晚期非小细胞肺癌预后评价中的价值
目的探讨外周血白蛋白和纤维蛋白原水平对晚期非小细胞肺癌(NSCLC)的临床预后价值。方法对2010年5月至2015年9月南京医科大学附属脑科医院胸科区收治的158例晚期非小细胞肺癌患者进行回顾性分析。所有患者均接受全身化疗加或不加局部放疗。收集患者临床病理特征及外周血蛋白、纤维蛋白原检测结果,分析外周血蛋白、纤维蛋白原水平与预后的相关性。结果血清白蛋白和血浆纤维蛋白原中位值分别为40.8 g/L (27.6 ~ 46.9 g/L)和3.4 g (2.4 ~ 5.2 g/L),血清白蛋白与纤维蛋白原比值(AFR)中位值为12.1(6.2 ~ 17.0)。血清白蛋白升高组(≥40 g/L)和血清白蛋白降低组(<40 g/L)的中位总生存期(OS)分别为17.0和9.0个月,血浆纤维蛋白原升高组(≥40 g/L)和血浆纤维蛋白原降低组(<40 g/L)的中位总生存期(OS)分别为9.0和17.0个月。AFR升高组(≥10)和AFR降低组(<10)的中位OS时间分别为17.0和8.0个月,两组间差异有统计学意义(均P < 0.01)。多因素分析显示,血清白蛋白水平(HR = 1.58, 95% CI 1.20 ~ 2.06, P = 0.003)、血浆纤维蛋白原水平(HR = 1.43, 95% CI 1.01 ~ 2.03, P = 0.046)和AFR (HR = 1.81, 95% CI 1.22 ~ 2.62, P = 0.001)是OS的独立预后因素。结论在晚期NSCLC患者中,较高的白蛋白水平和/或较低的纤维蛋白原水平与较好的临床预后相关。外周血白蛋白、纤维蛋白原水平和AFR是晚期非小细胞肺癌的独立预后因素。关键词:肺癌;非小细胞肺;白蛋白;纤维蛋白原;预后
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
肿瘤研究与临床
肿瘤研究与临床 Medicine-Oncology
CiteScore
0.10
自引率
0.00%
发文量
7737
期刊介绍: "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.
期刊最新文献
Progress of the relationship between breast cancer and thyroid diseases Analysis of cancer incidence and mortality in registration areas of Shanxi Province in 2014 Expressions of human epidermal growth factor receptor 2 in recurrent patients after radical gastrectomy and its significance Progress of molecular markers related to papillary thyroid carcinoma Significance of changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in neoadjuvant therapy for rectal cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1